12/20
05:46 pm
roiv
Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
Low
Report
Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
12/18
09:09 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/18
03:09 am
roiv
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
Medium
Report
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
12/15
02:30 pm
roiv
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
12/15
12:58 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.
12/15
08:44 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/12
10:02 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/11
07:30 am
roiv
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
Medium
Report
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
12/11
05:52 am
roiv
Immunovant drops 7%, prices $550M stock offering [Seeking Alpha]
Medium
Report
Immunovant drops 7%, prices $550M stock offering [Seeking Alpha]
11/20
06:35 am
roiv
Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]
Low
Report
Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]
11/16
01:10 am
roiv
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at
Wall Street Z
Medium
Report
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at
Wall Street Z
11/14
07:22 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/13
07:31 am
roiv
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]
Medium
Report
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]
11/11
03:35 pm
roiv
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.
11/11
10:38 am
roiv
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
Low
Report
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
11/11
07:03 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/10
12:34 pm
roiv
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript [Seeking Alpha]
11/10
08:05 am
roiv
Roivant Sciences GAAP EPS of -$0.17 beats by $0.16, revenue of $1.57M misses by $5.35M [Seeking Alpha]
Low
Report
Roivant Sciences GAAP EPS of -$0.17 beats by $0.16, revenue of $1.57M misses by $5.35M [Seeking Alpha]
11/10
07:00 am
roiv
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Low
Report
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
10/30
10:48 am
roiv
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at Citigroup Inc. from a "hold" rating to a "strong-buy" rating.
Low
Report
Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at Citigroup Inc. from a "hold" rating to a "strong-buy" rating.
10/29
10:09 am
roiv
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/27
04:10 pm
roiv
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Low
Report
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
10/21
10:02 am
roiv
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) [Yahoo! Finance]
Low
Report
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) [Yahoo! Finance]
10/5
05:18 am
roiv
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]
Low
Report
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]
10/4
05:11 pm
roiv
Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]
Low
Report
Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints [Yahoo! Finance]